System and method for monitoring molecular agents in vivo by estimating magnetic nanoparticle aggregation
View Patent ↗This invention provides a system and method for use of MSB with respect to nanoparticles to non-invasively so as to detect certain conditions, such as viral infection and immunological responses thereto. The system and method employs MSB, for example to detect and quantify antibody-specific NP aggregation to measure the concentration of molecular biomarkers in a wide variety of environments. The system and method can effectively differentiate antibody-specific aggregation from viscosity and temperature, which vary naturally in many environments we wish to explore. Advantageously, the system and method can provide a wide range of potential applications including, but not limited to, in vivo monitoring of immunotherapy efficacy, surgical site infection surveillance, chronic surgical pain monitoring and testing for contagions, which can be performed rapidly and at minimal cost in the field using (e.g.) unprocessed body fluid samples (blood, saliva, mucus and/or urine).
1 . A system for isolating magnetic nanoparticle-nanoparticle (NP-NP) binding/aggregation using coated magnetic NPs that bind selectively to at least one discrete compound associated with a biological process comprising:
a spectrometer adapted to:
scan a sample containing the at least one discrete compound associated with the biological process and infused with the coated magnetic NPs that bind selectively thereto;
apply magnetic fields from at least one drive coil that varies the magnetic fields in frequency and amplitude thereacross,
the frequency and amplitude varies independently for at least a portion of the magnetic fields causing viscosity changes in the sample to be distinguishable from bindings between coated magnetic NPs and causing non-specific bindings in the sample distinguishable from bindings between coated magnetic NPs; and
receive a signal indicative of a response spectra of the sample to the frequency and amplitude variations of the magnetic fields, the signal received from a first pickup coil having an axis that is at least one of (a) inline with and (b) perpendicular to a plane of the at least one drive coil,
wherein the response spectra includes a plurality of dimensions and the response spectra distinguishes coated magnetic NP-NP bindings from viscosity changes and from non-specific bindings; and
a computing device configured for determining whether NP-NP bindings in the sample response spectra is consistent with core size distribution and hydrodynamic size distribution estimates that are based on an initial size distribution of the NPs for the sample.
2 . The system as set forth in claim 1 , wherein a controller for the drive coil applies magnetic fields over a range of frequencies to identify scaling factors at each frequency, wherein a change in an average scaling factor is a surrogate for aggregation if a viscosity of the sample is known, or held constant before and after NP aggregation, or if the viscosity is not held constant, then the change in scaling factor over frequency can be used to identify and quantify changes in hydrodynamic size distribution as a surrogate for aggregation when viscosity of the sample is not held constant.
3 . The system as set forth in claim 1 , wherein a controller for the drive coil applies magnetic fields over a range of amplitudes sufficiently wide to identify scaling factors over amplitude, wherein a change in average scaling factor is a surrogate for aggregation if the temperature of the sample is known or held constant before and after NP aggregation, or the change in scaling factor over amplitude can be used to identify and quantify changes in the core size distribution as a surrogate for aggregation when the temperature of the sample is not held constant.
4 . The system as set forth in claim 1 , further comprising, a first perpendicular field coil that focuses at least some magnetization affecting the NPs in a plane perpendicular to a magnetic field of the drive coil to isolate feedthrough from the measured signal.
5 . The system as set forth in claim 4 , further comprising, a second perpendicular field coil that provides a magnetic field in a plane perpendicular to a magnetic field of the drive coil and perpendicular to the first perpendicular field coil.
6 . The system as set forth in claim 5 , further comprising, a second pickup coil arranged to detect the magnetization in the direction of the field of the drive coil and orthogonal to the axis of the first pickup coil.
7 . The system as set forth in claim 6 , wherein a controller is constructed and arranged to provide an alternating or variable drive currents to the first perpendicular field coil and the second perpendicular field coil adding two additional dimensions to the measured data, thereby allowing additional parameters to be estimated.
8 . The system as set forth in claim 7 , further comprising, a static magnetic field selectively applied to assist in the NP-NP binding.
9 . The system as set forth in claim 7 , further comprising, a strong magnetic field selectively applied to break NP-NP bonds.
10 . The system as set forth in claim 7 , further comprising, a predetermined ultrasound field selectively applied to break at least one of NP-NP bonds and NP binding to the compound.
11 . The system as set forth in claim 1 , wherein the compound comprises an antibody indicative of a disease of condition in the body.
12 . The system as set forth in claim 1 , further comprising, a process for measuring intracellular concentrations of biomarker molecules if the targeted NPs are introduced into cells.
13 . The system as set forth in claim 1 , further comprising, a process for binding different biomarker molecules with, respectively, different strength bonds in conjunction with the use of series of increasingly strong alternating magnetic fields to selectively break up sequentially stronger NP-NP bonds to measure multiple biomarker molecules in same probe.
14 . The system as set forth in claim 1 , further comprising a targeting process that targets a different size or shape of NPs for different, respective, biomarker molecules to measure multiple biomarkers using same probes.
15 . A method for estimating parameters of the size distribution, with or without aligning magnetic field with the system as set forth in claim 8 to, in turn, estimate a concentration of multiple biomarker molecules in the sample.
16 . A method for estimating applied fields with the system as set forth in claim 13 to, in turn, estimate a concentration of multiple biomarker molecules in the sample.
17 . A method for estimating the different size or shape of NPs with the system as set forth in claim 14 to, in turn, estimate a concentration of multiple biomarker molecules in the sample.
18 . The system as set forth in claim 1 , further comprising, a process for binding different biomarker molecules with, respectively, different strength bonds in conjunction with the use of ultrasound beams to selectively break up sequentially stronger NP-NP bonds to measure multiple biomarker molecules in same probe.
19 . The system of claim 1 , wherein the computing device processes aspects of the amplitude to provide core size distribution parameters associated with the aggregation of NPs.
20 . The system of claim 1 , wherein the computing device processes aspects of the frequency to provide hydrodynamic size distribution parameters associated with the aggregation of NPs.